Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,912 | 370 | 57.4% |
| Consulting Fee | $3,050 | 3 | 19.7% |
| Travel and Lodging | $2,384 | 3 | 15.4% |
| Unspecified | $1,122 | 3 | 7.2% |
| Education | $36.49 | 2 | 0.2% |
| Gift | $11.00 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biofrontera Inc. | $2,703 | 8 | $0 (2024) |
| Perrigo Company plc | $2,195 | 4 | $0 (2017) |
| AbbVie Inc. | $1,504 | 68 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,068 | 48 | $0 (2020) |
| Biofrontera Bioscience GmbH | $872.00 | 3 | $0 (2022) |
| Bausch Health US, LLC | $828.11 | 2 | $0 (2018) |
| Almirall LLC | $800.00 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $674.31 | 43 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $627.67 | 13 | $0 (2020) |
| PFIZER INC. | $500.15 | 27 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,283 | 4 | Biofrontera Inc. ($2,252) |
| 2023 | $184.20 | 5 | UCB, Inc. ($104.65) |
| 2022 | $1,025 | 5 | Biofrontera Bioscience GmbH ($872.00) |
| 2021 | $842.38 | 4 | Almirall LLC ($800.00) |
| 2020 | $515.35 | 19 | Regeneron Healthcare Solutions, Inc. ($140.76) |
| 2019 | $2,537 | 92 | AbbVie, Inc. ($565.84) |
| 2018 | $3,110 | 110 | Bausch Health US, LLC ($828.11) |
| 2017 | $5,019 | 143 | Perrigo Company plc ($2,195) |
All Payment Transactions
382 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $2.33 | General |
| Category: DERMATOLOGY | ||||||
| 06/14/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: DERMATOLOGY | ||||||
| 04/24/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.32 | General |
| Category: Immunology | ||||||
| 10/06/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: FACIAL AESTHETICS | ||||||
| 03/19/2023 | Amgen Inc. | AMJEVITA (Biological), Otezla | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Inflammation | ||||||
| 03/19/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $104.65 | General |
| 02/01/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: Immunology | ||||||
| 11/30/2022 | Biofrontera Bioscience GmbH | Ameluz (Drug), BF-RhodoLED XL | Food and Beverage | Cash or cash equivalent | $472.00 | General |
| Category: Dermatology | ||||||
| 11/30/2022 | Biofrontera Bioscience GmbH | Ameluz (Drug), BF-RhodoLED XL | Travel and Lodging | Cash or cash equivalent | $389.00 | General |
| Category: Dermatology | ||||||
| 11/19/2022 | Biofrontera Bioscience GmbH | Ameluz (Drug), BF-RhodoLED XL | Gift | Cash or cash equivalent | $11.00 | General |
| Category: Dermatology | ||||||
| 03/26/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $44.86 | General |
| 03/25/2022 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $108.19 | General |
| Category: DERMATOLOGY | ||||||
| 10/27/2021 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $15.16 | General |
| 06/23/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Immunology | ||||||
| 03/24/2021 | Almirall LLC | Klisyri (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Dermatology | ||||||
| 02/26/2021 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: Immunology | ||||||
| 08/26/2020 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 08/05/2020 | Janssen Biotech, Inc. | REMICADE (Biological), STELARA, SIMPONI | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Immunology | ||||||
| 03/17/2020 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug), DUOBRII | Food and Beverage | In-kind items and services | $11.83 | General |
| Category: DERMATOLOGY | ||||||
| 03/11/2020 | AbbVie Inc. | SKYRIZI (Biological), HUMIRA | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: IMMUNOLOGY | ||||||
| 03/05/2020 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $112.13 | General |
| Category: Immunology | ||||||
| 03/04/2020 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.02 | General |
| Category: Immunology | ||||||
| 02/21/2020 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $122.12 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $828.11 | 2 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | Biofrontera Inc. | $293.39 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 214 | 324 | $45,199 | $15,217 |
| 2022 | 9 | 220 | 259 | $49,002 | $15,719 |
| 2021 | 9 | 289 | 409 | $55,111 | $17,593 |
| 2020 | 9 | 276 | 371 | $50,524 | $16,020 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 104 | $18,258 | $6,182 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 31 | $7,700 | $2,666 | 34.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $6,731 | $2,224 | 33.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 24 | 29 | $5,726 | $1,901 | 33.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 24 | 26 | $2,850 | $1,076 | 37.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 18 | 22 | $2,878 | $794.95 | 27.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 11 | 81 | $1,056 | $373.47 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 80 | 105 | $18,738 | $6,060 | 32.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $7,262 | $2,291 | 31.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 21 | 28 | $5,675 | $1,825 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $3,615 | $1,281 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 14 | $3,530 | $1,195 | 33.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 13 | 15 | $3,357 | $1,048 | 31.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 20 | 23 | $3,047 | $886.68 | 29.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 16 | $1,775 | $569.26 | 32.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 14 | 14 | $2,003 | $562.61 | 28.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 100 | 129 | $23,140 | $7,471 | 32.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 38 | 40 | $8,207 | $2,325 | 28.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 28 | 28 | $6,165 | $1,846 | 29.9% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 13 | 15 | $3,349 | $1,340 | 40.0% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 12 | 13 | $3,329 | $1,312 | 39.4% |
| 17000 | Destruction of skin growth | Office | 2021 | 36 | 38 | $4,941 | $1,230 | 24.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 26 | 28 | $3,083 | $1,013 | 32.9% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 14 | 15 | $1,567 | $539.62 | 34.4% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 22 | 103 | $1,329 | $516.30 | 38.8% |
About Dr. John Tu, MD
Dr. John Tu, MD is a Dermatology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508897083.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Tu, MD has received a total of $15,516 in payments from pharmaceutical and medical device companies, with $2,283 received in 2024. These payments were reported across 382 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($8,912).
As a Medicare-enrolled provider, Tu has provided services to 999 Medicare beneficiaries, totaling 1,363 services with total Medicare billing of $64,549. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Rochester, NY
- Active Since 07/05/2006
- Last Updated 12/02/2010
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1508897083
Products in Payments
- AMELUZ (Drug) $2,703
- Humira (Biological) $1,082
- COSENTYX (Biological) $956.52
- Ameluz (Drug) $872.00
- Klisyri (Drug) $800.00
- EUCRISA (Drug) $497.03
- Otezla (Drug) $488.76
- DUPIXENT (Biological) $455.39
- TALTZ (Drug) $349.21
- Tremfya (Drug) $312.49
- Levulan (Drug) $289.26
- Enbrel (Biological) $272.25
- ILUMYA (Biological) $199.21
- DUPIXENT DUPILUMAB INJECTION (Biological) $186.48
- REMICADE (Biological) $177.09
- KERYDIN (Drug) $170.88
- Skyrizi (Biological) $153.91
- TREMFYA (Drug) $153.56
- ACZONE (Drug) $149.16
- SILIQ (Drug) $132.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Rochester
Lisa Beck, M.d, M.D
Dermatology — Payments: $937,192
Brett Shulman, Md, MD
Dermatology — Payments: $48,527
Afsaneh Alavi, Md, MD
Dermatology — Payments: $46,196
Anna De Benedetto, M.d, M.D
Dermatology — Payments: $41,746
Elizabeth Arthur, M.d, M.D
Dermatology — Payments: $20,989
Dr. Manasi Ladrigan, Md, MD
Dermatology — Payments: $15,181